Florian Brand helped start ATAI Life Sciences with one vision in mind: to effectively treat mental-health disorders by turning psychedelics into medicines.
Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses,
The investor base for companies creating psychedelic drugs can be categorized into three groups, Florian Brand of ATAI Life Sciences said: the visionaries, the “momentum investors,” and more recently, pharmaceutical and biotech investors.
BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that
ATAI Life Sciences and DemeRx are setting up a joint venture to develop a treatment for opioid dependence that works by giving people a “neurochemical reset.”
On Monday, GABA Therapeutics commenced dosing for its phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia.
Neuronasal is just the latest project for mental-health-focused ATAI. It has backed companies such as Compass Pathways, which is developing the psychedelic psilocybin, and Perception Neuroscience, which is working on a ketamine-like drug, both for the treatment of depression.
This week, GABA Therapeutics, a recent addition to the ATAI Life Sciences portfolio, announced
Since co-founding ATAI Life Sciences, I’ve been a firm believer in the power of psychedelic
Last week, Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences, spoke at the 10th
Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new joint venture aimed at battling mental health.
Berlin and Toronto, November11, 2019 ATAI Life Sciences AG, a global biotech platform that envisions
Psilocybin has shown promise for conditions like depression. Now, researchers are asking if the psychedelic experience is absolutely necessary to treat mental health.